X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the collaboration agreement, VeriSIM will leverage its proprietary BIOiSIM™ platform and Translational Index™ approach to reduce the number of outsourced preclinical experiments and help de-risk R&D decisions early-on to ensure expedited development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
The preclinical results of PT001 in this indication have been very encouraging. The development of this new therapy will directly improve the standard of care for PAH patients by reducing morbidity and enhancing the quality of life at a reasonable cost.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PT001
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
